Literature DB >> 24496319

The quality of quality: is it time for new tools?

Véronique L Roger1.   

Abstract

Entities:  

Keywords:  Editorials; hydroxymethylglutaryl-CoA reductase inhibitors; prevention & control

Mesh：

Substances：

Year:  2014        PMID： 24496319      PMCID： PMC3994999          DOI： 10.1161/CIRCULATIONAHA.114.008390

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  20 in total

1.  Do optimal antihypertensive drug regimens allow blood pressure normalization in all patients with resistant hypertension?

Authors:  Bernard Waeber; François Feihl
Journal:  Hypertension       Date:  2013-08-05       Impact factor: 10.190

2.  Increasing demands for quality measurement.

Authors:  Robert J Panzer; Richard S Gitomer; William H Greene; Patricia Reagan Webster; Kevin R Landry; Charles A Riccobono
Journal:  JAMA       Date:  2013-11-13       Impact factor: 56.272

3.  Reliable and sustainable comprehensive care for frail elderly people.

Authors:  Joanne Lynn
Journal:  JAMA       Date:  2013-11-13       Impact factor: 56.272

4.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

5.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

6.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Authors:  Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene
Journal:  N Engl J Med       Date:  2004-03-08       Impact factor: 91.245

7.  Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

Authors:  Brent M Egan; Yumin Zhao; Jiexiang Li; W Adam Brzezinski; Thomas M Todoran; Robert D Brook; David A Calhoun
Journal:  Hypertension       Date:  2013-08-05       Impact factor: 10.190

8.  Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction.

Authors:  Suzanne V Arnold; Mikhail Kosiborod; Fengming Tang; Zhenxiang Zhao; Thomas M Maddox; Patrick L McCollam; Julie Birt; John A Spertus
Journal:  Circulation       Date:  2014-02-04       Impact factor: 29.690

9.  Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.

Authors:  Suzanne V Arnold; John A Spertus; Frederick A Masoudi; Stacie L Daugherty; Thomas M Maddox; Yan Li; John A Dodson; Paul S Chan
Journal:  J Am Coll Cardiol       Date:  2013-08-21       Impact factor: 24.094

10.  Validity of electronic health record-derived quality measurement for performance monitoring.

Authors:  Amanda Parsons; Colleen McCullough; Jason Wang; Sarah Shih
Journal:  J Am Med Inform Assoc       Date:  2012-01-16       Impact factor: 4.497
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.